No better than less expensive drugs

BMJ. 2012 Apr 24:344:e2914. doi: 10.1136/bmj.e2914.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / economics*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Humans
  • Hypoglycemic Agents / economics*
  • Hypoglycemic Agents / therapeutic use

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents